GLP1-S

About GLP1-S

Originally developed as a medication to treat Type-2 diabetes, GLP1-S has been adopted as an effective tool to combat obesity in recent years. It is a glucagon-like peptide-1 (GLP-1) receptor agonist, which mimics the GLP-1 hormone. GLP-1 is a gut hormone released in response to eating; in higher amounts, it interacts with the brain to suppress appetite and create a lasting feeling of fullness. In clinical trials, after 68 weeks, half of participants lost 15–17% of their initial body weight, and roughly a third lost 20% with improved diet and exercise. Many individuals regained weight after stopping the medication, which highlights the importance of a long-term strategy.

Dosing & Reconstitution Guide

— 5 mg Vial —

Reconstitute: Mix 5 mg with 1.0 mL (100 units) of bacteriostatic water → 5 mg/mL concentration.
Administration: Subcutaneous injection.
Timing: Dose once weekly, on the same day each week. If prone to side effects, take the dose before bedtime.
Storage: Lyophilized: freeze at −20 °C; reconstituted: refrigerate at 2–8 °C, avoid freeze-thaw cycles.

Schedule: One dose every 7 days. Remain on each dose for a minimum of 4 weeks before increasing.
Goal: Appetite suppression, improved glycemic control, and sustained weight reduction.

Syringe (U-100)	Dose
5 units (0.05 mL)	0.25 mg
10 units (0.10 mL)	0.5 mg
15 units (0.15 mL)	0.75 mg
20 units (0.20 mL)	1 mg
25 units (0.25 mL)	1.25 mg
30 units (0.30 mL)	1.5 mg
35 units (0.35 mL)	1.75 mg
40 units (0.40 mL)	2 mg
45 units (0.45 mL)	2.25 mg
50 units (0.50 mL)	2.5 mg

— 10 mg Vial —

Reconstitute: Mix 10 mg with 2.0 mL (200 units) of bacteriostatic water → 5 mg/mL concentration.
Administration: Subcutaneous injection.
Timing: Dose once weekly, on the same day each week.
Storage: Lyophilized: freeze at −20 °C; reconstituted: refrigerate at 2–8 °C, avoid freeze-thaw cycles.

Schedule: One dose every 7 days. Remain on each dose for a minimum of 4 weeks before increasing.
Goal: Appetite suppression, improved glycemic control, and sustained weight reduction.

Syringe (U-100)	Dose
5 units (0.05 mL)	0.25 mg
10 units (0.10 mL)	0.5 mg
15 units (0.15 mL)	0.75 mg
20 units (0.20 mL)	1 mg
25 units (0.25 mL)	1.25 mg
30 units (0.30 mL)	1.5 mg
35 units (0.35 mL)	1.75 mg
40 units (0.40 mL)	2 mg
45 units (0.45 mL)	2.25 mg
50 units (0.50 mL)	2.5 mg

Benefits

• Significant weight loss: after 68 weeks in clinical trials, half of participants lost ~17% of initial body weight; another third lost 20% with improved diet and exercise.
• Reduces risk of major cardiovascular events (death, heart attack, or stroke) in adults with heart disease.
• Potent anti-inflammatory effects.
• Helps reduce amyloid protein buildup in the brain (linked to Alzheimer’s disease).
• Shown potential in treating substance use disorders by reducing cravings.
• Improves blood sugar regulation.
• Lowers risk of COVID-19-related complications.
• Fewer outbreaks of hidradenitis suppurativa.

Side Effects

Of all GLP-1 medications, GLP1-S has one of the highest rates of side effects. These may include:

• Nausea
• Diarrhea
• Vomiting
• Constipation
• Abdominal pain
• Headache
• Fatigue
• Dizziness
• Sulfur-smelling burps
• Gas and bloating
• Heartburn
• Runny nose
• Sore throat

Less common but more serious side effects:

• Thyroid tumors and/or cancer
• Inflammation of the pancreas (pancreatitis)
• Gallbladder disease
• Gastroparesis (stomach paralysis)
• Kidney failure
• Changes in vision (especially for diabetics)
• Depression or suicidal ideation
• Increased heart rate
• Hypoglycemia (especially if combined with insulin or sulfonylureas)

Contraindications

Do NOT take GLP1-S if:

• You are allergic or hypersensitive to any ingredients
• You are pregnant or breastfeeding
• You have thyroid disease
• You or your family has a history of medullary thyroid cancer
• You have Multiple Endocrine Neoplasia Syndrome Type 2 (MEN 2)
• You have gallbladder disease or pancreatitis

Consult your physician before use if you have:

• Hypoglycemia
• Chronic eye disease
• Severe gastrointestinal disorders
• Pancreatic or kidney problems
• Type-2 diabetes with diabetic retinopathy
• Upcoming surgery or procedures using anesthesia

Stacking Suggestions

Common research pairings with GLP1-S include:

• AOD-9604 – Improves fat loss, supports body recomposition, and helps break plateaus during GLP1-S use
• L-Carnitine – Enhances energy and fat oxidation, especially helpful for users experiencing fatigue
• NAD+ – Supports mitochondrial repair and boosts metabolism and cellular energy
• BPC-157 / TB-500 – Reduce gut inflammation, promote healing, and improve systemic resilience under calorie restriction
• CJC No DAC / Ipamorelin – Preserves lean muscle and supports GH signaling, making weight loss safer and more sustainable
• Glutathione – Supports liver function, detox pathways, and systemic inflammation reduction
• Pancragen – May help reduce desensitization in long-term users

Research Sources

Citations for verification. Many studies are animal/in-vitro.

1. Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1 trial). N Engl J Med. 2021;384(11):989-1002. PMID: 33567185
2. Marso SP, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes (SUSTAIN-6). N Engl J Med. 2016;375(19):1834-1844. PMID: 27633186
3. SELECT trial: semaglutide reduced major adverse cardiovascular events in adults with overweight/obesity and established cardiovascular disease without diabetes (N Engl J Med, 2023).